Reference:GBR MEDDEV 2.7/3 revision 3 May-2015 7.1: Difference between revisions
From GxPlex
gxplex>GxPlexBot Import from GxPlex Excel |
Gxplex admin (talk | contribs) m 1 revision imported |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{ | {{ReferenceData | ||
| | |has_document=Document:GBR MEDDEV 2.7/3 revision 3 May-2015 | ||
| | |module=5 | ||
| | |unit=5.3.6 | ||
| | |scope=MD | ||
| | |doc_part=7.1 | ||
| | |language=EN | ||
|entry_by=Florian Adragna | |||
|contributors= | |||
|tags=TAG-00253-Rep-att ++ TAG-00046-Ser-sSc ++ TAG-00069-Imm-rhe ++ TAG-00017-Spo-die ++ TAG-00201-Cli-eSt | |||
|tags_display=[[Glossary:TAG-00253-Rep-att|Reporting timeline]], [[Glossary:TAG-00046-Ser-sSc|Serious adverse event]], [[Glossary:TAG-00069-Imm-rhe|Urgent safety measure]], [[Glossary:TAG-00017-Spo-die|Sponsor]], [[Glossary:TAG-00201-Cli-eSt|Clinical investigation]] | |||
|comment=Reporting timelines for SAEs to NCAs | |||
|content=7. REPORTING TIMELINES | |||
| | |||
| | |||
7. REPORTING TIMELINES | |||
7.1 Report by sponsor to NCAs. | 7.1 Report by sponsor to NCAs. | ||
The sponsor must report to the NCAs where the clinical investigation has commenced: | The sponsor must report to the NCAs where the clinical investigation has commenced: | ||
| Line 47: | Line 17: | ||
- any other reportable events as described in section 4 or a new finding/update to it: immediately, but not later than 7 calendar days following the date of awareness by the sponsor of the new reportable event or of new information in relation with an already reported event. | - any other reportable events as described in section 4 or a new finding/update to it: immediately, but not later than 7 calendar days following the date of awareness by the sponsor of the new reportable event or of new information in relation with an already reported event. | ||
[...] | [...] | ||
}} | |||
Latest revision as of 13:50, 16 July 2026
| Document information | |
|---|---|
| Reference | GBR MEDDEV 2.7/3 revision 3 May-2015 |
| Validity area | GBR |
| Scope(s) | MD |
| Document name | MEDDEV 2.7/3 revision 3 |
| Version / Revision | May-2015 |
| Status | Current |
| Document type | Official guideline |
| Language(s) | EN |
| Description | GUIDELINES ON MEDICAL DEVICES CLINICAL INVESTIGATIONS:
SERIOUS ADVERSE EVENT REPORTING UNDER DIRECTIVES 90/385/EEC AND 93/42/EEC. |
| Official source | Official link |
| Restricted access | No |
| Submitted by | Florian Adragna |
| Contributors | |
| Reference Details | |
|---|---|
| Module | Module 5 — Unit 5.3.6 |
| Scope | MD |
| Document part | 7.1 |
| Language | EN |
| Original entry by | Florian Adragna |
| Contributors | |
| Tags | Reporting timeline, Serious adverse event, Urgent safety measure, Sponsor, Clinical investigation |
Content
7. REPORTING TIMELINES 7.1 Report by sponsor to NCAs. The sponsor must report to the NCAs where the clinical investigation has commenced: - for all reportable events as described in section 4 which indicate an imminent risk of death, serious injury, or serious illness and that requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it: immediately, but not later than 2 calendar days after awareness by sponsor of a new reportable event or of new information in relation with an already reported event. - any other reportable events as described in section 4 or a new finding/update to it: immediately, but not later than 7 calendar days following the date of awareness by the sponsor of the new reportable event or of new information in relation with an already reported event. [...]
